To ensure the accuracy of our patient satisfaction scores, we require that providers who see patients receive
a minimum number of completed patient-submitted surveys before their reviews are listed on their profiles.
Star ratings on this site are collected on a rolling basis from the previous 12 months.
Additionally, some of the physicians listed on our site do not see patients directly, and therefore, do not receive
evaluation and ratings from patients.
Interim Chair, Microbiology and Immunology; Professor and Director, Center for Metabolic Disease Research; Professor, Pharmacology, Sol Sherry Thrombosis Research Center, and Cardiovascular Research Center, Lewis Katz School of Medicine, Temple University
EMBA, The Fox School of Business, Temple University, Philadelphia, PA, 2009
Postdoctoral Fellow, Harvard School of Public Health, Boston, 1997
PhD, University of Montreal, Montreal, Canada 1996
MSc, Peking Union Medical College, Beijing, China,1985
MD, Jiang Xi Medical School, Nanchang, China, 1979
The Wang laboratory studies pathological and metabolic changes in cardiovascular diseases, including hyperlipidemia, hyperglycemia, hyperinsulinemia, hyperhomocysteinemia, obesity, vascular inflammation, diabetes, stroke, peripheral artery disease, myocardial infarction, and chronic kidney disease. Researches focus on investigating the effect and underlying mechanism of metabolic disorder on 1) Atherosclerosis and vascular inflammation, 2) Endothelial function, 3), Monocyte epitope mapping/polarization, 4) HDL metabolism, 5) Epigenetic modification, and 6) Gene and stem cell therapy. We use dynamic state-of-art technologies to dissect disease mechanism and identify potential therapeutic targets. Frequently used research approaches include metabolomics, transcriptomics, RNA-Seq, CHIP-Seq, chemical, biochemical, immunological and pathophysiological approaches, microsurgery models for various vascular disease and thrombosis, transgenic and gene knock-out mice.
11806997. Wang H, Yoshizumi M, Lai K-H, Tsai J-C, Haber E, Lee M-E Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem (1997) 272:25380-25385
11806997. Wang H‡, Jiang XH, Yang F, Chapman GB, Durante W, Sibinga NES, Schafer AI, Cyclin A transcriptional suppression is the major mechanism mediating homocysteine-induced endothelial cell growth inhibition, Blood, (2002) 99:939-945, ‡ Corresponding author,
12506016. Wang H‡, Jiang XH, Yang F, Gaubatz JW, Ma L, Magera MJ, Yang XF, Berger PB, Durante W, Pownall HJ, Schafer AI, Hyperhomocysteinemia accelerates atherosclerosis in cystathionine -synthase and apolipoprotein E double knockout mice with and without dietary perturbation, Blood, (2004) 101:3901-3907, ‡ Corresponding author
16226235. Tan HM, Jiang XH, Yang F, Li ZH, Liao D, Trial J, Magera M, Durante W, Yang XF, Wang H, Hyperhomocysteinemia inhibits post injury re-endothelialization in mice, Cardiovascular Res, (2006) 69:253-262
16226235. Jiang XH, Yang F, Tan HM, Liao D, Bryan RM Jr., Durante W, Rumbaut RE, Yang XF, Wang H, Hyperhomocysteinemia impairs endothelial function and eNOS activity via protein kinase C activation, Arterioscler Thromb Vasc Biol., (2005) 25:2515-2521
16931800. Liao D, Tan HM, Hui RT, Li ZH, Jiang XH, Yang F, Gaubatz JW, Durante W, Chan L, Schafer AI, Pownall HJ, Yang XF, Wang H. Hyperhomocysteinemia Decreases Circulating High-Density Lipoprotein by Inhibiting Apolipoprotein A-I Protein Synthesis and Enhancing HDL Cholesterol Clearance. Circ. Res. (2006) 99:598-606, [Accompanied by an Editorial: Circ. Res. 99:565-566]
17715404. Jiang XH, Yang F, Brailoiu E, Jakubowski H, Dun NJ, Schafer AI, Yang XF, Durante W and Wang H, Differential regulation of homocysteine transport in vascular endothelial and smooth muscle cells, Arterioscler. Thromb. Vasc. Biol. (2007) 27:1976-83
17698632. Jamaluddin SM, Chen I, Yang F, Jiang XH, Jan M, Liu XM, Schafer AI, Durante W, Yang XF, and Wang H, Homocysteine inhibits endothelial cell growth via DNA hypomethylation of the cyclin A gene. Blood (2007) 110:3648-3655, [Accompanied by an Editorial: Blood,110:3495-3496]
19578482. Yang, XF, Yin, Y, Wang, H, Vascular inflammation and atherosclerosis are activated via receptors for PAMPs and suppressed by regulatory T cells. Drug Discovery Today, (2008)5:125-142
19858416. Zhang, D, Jiang, X, Pu, F, Yan Y, Song, J, Gupta, S, Schafer, AI, Durante, W, Kruger, W, Yang, XF and Wang, H., Hyperhomocysteinemia promotes inflammatory monocyte generation and accelerates atherosclerosis in transgenic CBS deficient mice. Circulation (2009) 120:1893-1902
20305127. Chen NC, Yang F, Capecci LM, Gu ZY, Schafer AI, Durante W, Yang XF, Wang H, Regulation of homocysteine metabolism and methylation in human and mouse tissues, The FASEB Journal, (2010) 24(8):2804-17
21653942. Cheng ZJ, Jiang XH, Kruger WD, Praticò D, Gupta S, Mallilankaran K, Muniswamy M, Schafer AI, Durante W, Yang XF, Wang H, Hyperhomocysteinemia impairs endothelium-derived hyperpolarizing factor-mediated vasorelaxation in transgenic cystathionine beta-synthase-deficient mice, Blood, (2011) 118:1998-2006 [Accompanied by an Editorial: Blood,118:1717-1719
22202099. Pansuria M, Xi H, Li L, Yang XF, Wang H. (2012) Insulin resistance, metabolic stress, and atherosclerosis, Frontiers in Bioscienc 1;4:916-31
22628578. Zhang DQ, Fang P, Jiang XH, Nelson J, Moore JK, Kruger WD, Berretta RM, Houser SR, Yang XF, Wang H, Severe hyperhomocysteinemia promotes bone marrow-derived and resident inflammatory monocyte differentiation and atherosclerosis in LDLr/CBS-deficient mice, (2012) Circ Res, 111:37-49
The following ratings and reviews are based on verified feedback collected from independently administered
patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions.
Patient identities are withheld to ensure confidentiality and privacy.
Learn more about our Patient Experience Ratings.